Emami
- Market Cap
- ₹18,429 Cr
- P/E
- 24.76
Key Fundamentals
SmallcapPersonal ProductsFMCGPrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 28.10%
- Debt to Equity
- 0.08
- EPS (TTM)
- ₹17.05
- Book Value
- ₹67.03
- Market Cap
- ₹18,429 Cr
- P/E (TTM)
- 24.76
- P/B
- 6.30
- ROE
- 26.20%
- Dividend Yield
- 1.18%
- EBITDA
- ₹1,049 Cr
- 52W High
- ₹550.90
- 52W Low
- ₹357.00
- Day Range
- ₹419.50 – ₹425.00
- Volume
- 3,09,278
Peer Comparison
Fast Moving Consumer Goods › Personal Products › Personal Care
| 919.50 | 47.57 | 94,093 | 7.46 | 1.67% | 16.10% | 18.80% | 16,537 | 1,978 | |
| 393.10 | 34.42 | 69,734 | 6.07 | 0.92% | 17.00% | 20.30% | 13,924 | 2,001 | |
| 365.65 | 290.20 | 49,168 | 87.48 | 1.38% | 27.60% | 33.90% | 602 | 169 | |
| 1,760.00 | 35.15 | 47,869 | 29.60 | 1.42% | 82.70% | 108.00% | 6,391 | 1,362 | |
| 7,090.50 | 33.80 | 23,105 | 21.51 | 3.31% | 66.50% | 90.70% | 3,211 | 683 | |
| 7,020.00 | 29.34 | 22,787 | 25.78 | 3.73% | 115.00% | 157.00% | 4,240 | 776 | |
| 422.20 | 24.76 | 18,429 | 6.30 | 1.21% | 26.20% | 28.10% | 4,204 | 747 | |
| Median 7 companies | 919.50 | 34.42 | 47,869 | 21.51 | 1.42% | 27.60% | 33.90% | 4,240 | 776 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 82
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 45
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 57
- Good
- Sales & profit trajectory 9% weight
- Financial Health
- 90
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 65
- Good
- Trend strength, vol-adjusted 12% weight
- Ownership
- 48
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
4- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 28.5%
- Company has been maintaining a healthy dividend payout of 52.9%
- Debtor days have improved from 42.3 to 33.2 days.
Weaknesses
1- The company has delivered a poor sales growth of 5.58% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 6 | 1 | 12 |
| Oscillators | Strong Bearish | 5 | 1 | 3 |
| Moving Averages | Strong Bullish | 1 | 0 | 9 |
Oscillators
Strong Bearish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 70.10
- Bearish
- MACD (12,26,9)
- 11.58
- Bullish
- SMA (50)
- 383.33
- Bullish
- SMA (200)
- 413.75
- Bullish
As of
Analyst Rating
19 of 22 analysts rate Buy, 3 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +4.83% |
|---|---|
| 5Y | +5.58% |
| 3Y | +3.53% |
| 1Y | −0.76% |
| TTM | +13.16% |
Net profit
| 10Y | +7.88% |
|---|---|
| 5Y | +11.24% |
| 3Y | +7.32% |
| 1Y | −3.49% |
| TTM | −0.80% |
Operating cash flow
| 10Y | +3.61% |
|---|---|
| 5Y | −2.77% |
| 3Y | +2.26% |
| 1Y | −10.60% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −3.78 pp |
|---|---|
| 5Y | −5.14 pp |
| 3Y | +0.30 pp |
| 1Y | −1.22 pp |
| TTM | −1.17 pp |
Revenue by year
| Mar 2017 | ₹2,488 Cr |
|---|---|
| Mar 2018 | ₹2,531 Cr |
| Mar 2019 | ₹2,695 Cr |
| Mar 2020 | ₹2,655 Cr |
| Mar 2021 | ₹2,881 Cr |
| Mar 2022 | ₹3,192 Cr |
| Mar 2023 | ₹3,406 Cr |
| Mar 2024 | ₹3,578 Cr |
| Mar 2025 | ₹3,809 Cr |
| Mar 2026 | ₹3,780 Cr |
Net profit by year
| Mar 2017 | ₹340 Cr |
|---|---|
| Mar 2018 | ₹306 Cr |
| Mar 2019 | ₹303 Cr |
| Mar 2020 | ₹302 Cr |
| Mar 2021 | ₹455 Cr |
| Mar 2022 | ₹837 Cr |
| Mar 2023 | ₹627 Cr |
| Mar 2024 | ₹724 Cr |
| Mar 2025 | ₹803 Cr |
| Mar 2026 | ₹775 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Emami Ltd trades at ₹412.6 as of 2026-11-17 with a market cap of ₹18,010 Cr, a PE of 24.2x, and a near-debt-free balance sheet (debt-to-equity of 0.06). The company demonstrates strong return ratios with a 5-year average ROE of 31% but faces headwinds from sluggish long-term sales and profit growth alongside a stock price that has declined 21% over the past year.
- Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.06, providing significant financial flexibility and resilience against interest rate cycles.
- Excellent return on equity track record with a 5-year average ROE of 31% and a 3-year average of 28%, well above most FMCG peers, indicating efficient capital allocation.
- ROCE stands at 28.59% as of 2026-11-17, reflecting strong operating profitability and efficient use of total capital employed.
- Healthy dividend payout ratio of 52.9% with a current dividend yield of 1.21%, rewarding shareholders consistently while retaining enough for growth.
- TTM sales growth has accelerated to 13%, a notable improvement over the 3-year compounded sales growth of 4% and 5-year CAGR of 6%, suggesting a possible revenue inflection.
- Improvement in working capital efficiency with debtor days declining from 42.3 to 33.2 days, indicating better cash conversion and receivables management.
- 10-year ROE has been sustained at 26%, demonstrating long-term consistency in generating shareholder returns across business cycles.
- Stock has delivered negative returns across all measured horizons — 1-year CAGR of -21%, 3-year CAGR of -6%, 5-year CAGR of -4%, and 10-year CAGR of -3% — indicating persistent value erosion for shareholders.
- Compounded sales growth has been tepid at just 5% over 10 years and 4% over 3 years, reflecting limited ability to scale revenues meaningfully in a competitive FMCG landscape.
- TTM profit growth is flat at 0% despite TTM sales growing 13%, suggesting margin compression or rising costs that are eating into bottom-line expansion.
- Compounded profit growth of only 5% over 3 years and 6% over 10 years lags behind broader FMCG sector growth rates, raising questions about long-term earnings scalability.
- PE of 24.2x on an EPS of ₹17.05 demands sustained earnings acceleration to justify the valuation, yet the 5-year compounded profit growth of 11% has moderated to 0% on a TTM basis.
- The stock sits only 15.6% above its 52-week low of ₹357, and is down substantially from its 52-week high of ₹550.9, reflecting weak market sentiment and potential further downside risk.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Emami is showing strong topline momentum with high-double digit October sales growth and guided 18-20% core H2 growth. Promoter pledge levels are trending down, a modest positive for sentiment. Key risks include higher-than-guided strategic investments and persistent input cost pressure delaying margin expansion. The operational trend is improving, but margin recovery remains a next-year story.
- Strategic investment overshoot Nov 6
Strategic investment run rate at ₹1,000-1,100 crore versus earlier guidance of ₹800-850 crore, indicating higher-than-expected spending that could weigh on near-term profitability.
- High input cost pressure Nov 6
Gross margins improvement is projected only for next year, implying current elevated input costs continue to compress margins in the near term.
- Strong October sales momentum Nov 6
October sales reported high-double digit growth. Core business expected to grow 18-20% in H2FY27, signaling robust demand recovery.
- Promoter releases pledged shares Nov 14
Diwakar Finvest and Suraj Finvest released pledged Emami shares to DCB Bank, HSBC, and IDBI. Diwakar's encumbered holding now stands at 5.43% of total share capital, reflecting improving promoter financial health.
- Promoter pledge adjustments Oct 30
Diwakar Finvest released 41 lakh shares while Suraj Finvest pledged 21.4 lakh shares in late October 2026, resulting in a net release of roughly 19.6 lakh shares.
- KMP disclosure list updated Nov 5
Emami disclosed authorized Key Managerial Personnel for materiality determination and disclosures under SEBI Listing Regulations, effective November 5, 2026.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 865 | 996 | 891 | 906 | 891 | 1,049 | 963 | 904 | 799 | 1,152 | 925 | 1,039 | 1,088 |
| Expenses | 632 | 682 | 682 | 692 | 645 | 715 | 744 | 692 | 622 | 768 | 739 | 815 | 866 |
| Operating Profit | 233 | 314 | 209 | 214 | 246 | 334 | 219 | 212 | 177 | 384 | 186 | 225 | 222 |
| OPM % | 27% | 32% | 24% | 24% | 28% | 32% | 23% | 23% | 22% | 33% | 20% | 22% | 20% |
| Other Income | 11 | 11 | 11 | 10 | 22 | 15 | 21 | 22 | 21 | 18.97 | 23 | 18 | 23 |
| Interest | 2 | 3 | 3 | 2 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 6 | 6 |
| Depreciation | 46 | 46 | 48 | 44 | 45 | 46 | 44 | 44 | 45 | 45 | 42 | 43 | 45 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | −10.15 | — | — | — |
| PBT | 196 | 276 | 169 | 178 | 220 | 301 | 194 | 187 | 150 | 345 | 164 | 195 | 194 |
| Tax % | 8% | 6% | 13% | 16% | 4% | 7% | 16% | 12% | 1% | 7% | 13% | 29% | 25% |
| Net Profit | 180 | 261 | 147 | 151 | 211 | 279 | 162 | 164 | 148 | 319 | 143 | 139 | 146 |
| EPS (₹) | 4.09 | 5.92 | 3.41 | 3.50 | 4.87 | 6.39 | 3.72 | 3.76 | 3.40 | 7.32 | 3.28 | 3.15 | 3.30 |
| YoY Sales growth | 6 | 1 | 7 | 10 | 3 | 5 | 8 | 0 | −10 | 10 | −4 | 15 | 36 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,076 | 2,358 | 2,488 | 2,531 | 2,695 | 2,655 | 2,881 | 3,192 | 3,406 | 3,578 | 3,809 | 3,780 | 4,204 |
| Expenses | 1,536 | 1,670 | 1,729 | 1,812 | 1,970 | 1,970 | 2,000 | 2,254 | 2,550 | 2,632 | 2,796 | 2,820 | 3,187 |
| Operating Profit | 541 | 688 | 759 | 719 | 725 | 685 | 880 | 938 | 855 | 946 | 1,014 | 960 | 1,017 |
| OPM % | 26% | 29% | 31% | 28% | 27% | 26% | 31% | 29% | 25% | 26% | 27% | 25% | 24% |
| Other Income | 91 | 44 | 31 | 19 | 25 | 46 | 69 | 90 | 69 | 41 | 68 | 85.11 | 74 |
| Interest | 5 | 54 | 58 | 34 | 21 | 21 | 13 | 5 | 7 | 10 | 9 | 11 | 18 |
| Depreciation | 34 | 255 | 309 | 311 | 325 | 336 | 367 | 335 | 247 | 186 | 178 | 177 | 176 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | — | — | −10.15 | — |
| PBT | 592 | 423 | 424 | 393 | 403 | 374 | 569 | 688 | 670 | 791 | 894 | 846 | 897 |
| Tax % | 18% | 14% | 20% | 22% | 25% | 19% | 20% | −22% | 6% | 8% | 10% | 8% | — |
| Net Profit | 485 | 363 | 340 | 306 | 303 | 302 | 455 | 837 | 627 | 724 | 803 | 775 | 747 |
| EPS (₹) | 10.70 | 8.00 | 7.50 | 6.77 | 6.68 | 6.67 | 10.23 | 19.02 | 14.50 | 16.58 | 18.48 | 17.76 | 17.05 |
| Div. Payout % | 33% | 44% | 47% | 52% | 60% | 60% | 78% | 42% | 55% | 48% | 54% | 56% | — |
| Sales growth | 22 | 14 | 6 | 2 | 6 | −1 | 8 | 11 | 7 | 5 | 6 | −1 | 13 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 45 | 45 | 44 | 44 | 44 | 44 | 44 | 44 | 44 |
| Reserves | 1,208 | 1,589 | 1,732 | 1,991 | 2,031 | 1,778 | 1,718 | 2,032 | 2,259 | 2,403 | 2,651 | 2,880 | 2,882 |
| Borrowings | 36 | 671 | 473 | 326 | 110 | 210 | 101 | 282 | 91 | 94 | 90 | 162 | 231 |
| Other Liabilities | 410 | 409 | 376 | 458 | 633 | 644 | 656 | 692 | 703 | 728 | 741 | 745 | 1,329 |
| Total Liabilities | 1,676 | 2,692 | 2,603 | 2,798 | 2,819 | 2,678 | 2,520 | 3,050 | 3,096 | 3,269 | 3,525 | 3,831 | 4,485 |
| Fixed Assets | 453 | 1,918 | 1,994 | 1,802 | 1,680 | 1,459 | 1,132 | 1,344 | 1,245 | 1,114 | 984 | 886 | 1,684 |
| CWIP | 29 | 67 | 22 | 30 | 36 | 8 | 6 | 3 | 6 | 8 | 15 | 1 | 2 |
| Investments | 501 | 104 | 128 | 314 | 187 | 156 | 255 | 303 | 293 | 442 | 676 | 834 | 502 |
| Other Assets | 693 | 604 | 460 | 652 | 915 | 1,055 | 1,126 | 1,400 | 1,551 | 1,706 | 1,850 | 2,108 | 2,297 |
| Total Assets | 1,676 | 2,692 | 2,603 | 2,798 | 2,819 | 2,678 | 2,520 | 3,050 | 3,096 | 3,269 | 3,525 | 3,831 | 4,485 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 534 | 562 | 730 | 588 | 554 | 531 | 922 | 644 | 749 | 779 | 896 | 801 |
| Investing | −237 | −1,313 | −306 | −276 | −26 | −231 | −224 | −234 | −122 | −210 | −345 | −174 |
| Financing | −215 | 502 | −496 | −324 | −428 | −405 | −688 | −402 | −608 | −563 | −500 | −554 |
| Net Cash Flow | 82 | −249 | −72 | −12 | 100 | −106 | 9 | 8 | 19 | 6 | 52 | 72 |
| Free Cash Flow | 426 | 430 | 448 | 465 | 421 | 383 | 890 | 164 | 719 | 750 | 852 | 770 |
| CFO/EBITDA | 116 | 96 | 105 | 93 | 89 | 89 | 115 | 84 | 101 | 98 | 107 | 101 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 18 | 20 | 14 | 22 | 29 | 42 | 29 | 37 | 44 | 50 | 43 | 33 |
| Inventory Days | 59 | 68 | 83 | 87 | 88 | 102 | 118 | 121 | 100 | 102 | 94 | 128 |
| Days Payable | 90 | 112 | 85 | 109 | 115 | 135 | 138 | 138 | 124 | 143 | 133 | 153 |
| Cash Conversion Cycle | −13 | −24 | 12 | 1 | 2 | 9 | 10 | 19 | 20 | 9 | 4 | 8 |
| Working Capital Days | −16 | −54 | −62 | −32 | −6 | 7 | −3 | 0 | 28 | 30 | 25 | 21 |
| ROCE % | 61% | 30% | 23% | 22% | 19% | 18% | 29% | 31% | 28% | 32% | 32% | 28% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Emami insights
78 extracted metrics across FY11–FY27.
Documents
- Q2 FY27 concall · Nov 2026PPT
- Q2 FY27 concall · Nov 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q1 FY27 concall · Aug 2026PPT
- Q4 FY26 concall · May 2026Transcript PPT Recording
- 17 Dec 2025
- 16 Oct 2025
- 19 Sep 2024
- 30 Oct 2023
- 3 Oct 2023
Frequently Asked Questions about Emami
What does Emami Ltd do?
Where is Emami Ltd (EMAMILTD) listed?
Which sector does Emami Ltd belong to?
What is the market capitalisation of Emami Ltd?
What is the PE ratio of Emami Ltd?
What is the 52-week high and low of Emami Ltd?
Does Emami Ltd pay dividends?
What is the Return on Equity (ROE) of Emami Ltd?
Company Information
Emami is engaged in manufacturing & marketing of personal care & healthcare products with an enviable portfolio of household brand names such as BoroPlus, Navratna, Fair and Handsome, Zandu Balm, Kesh King, Zandu Pancharishta, Mentho Plus Balm and others.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/EMAMILTD.md for Emami Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.